|
[1]
|
Gedam, M. and Zheng, H. (2024) Complement C3aR Signaling: Immune and Metabolic Modulation and Its Impact on Alzheimer’s Disease. European Journal of Immunology, 54, e2350815.
https://doi.org/10.1002/eji.202350815
|
|
[2]
|
Nonaka, M. and Kimura, A. (2006) Genomic View of the Evolution of the Complement System. Immunogenetics, 58, 701-713.
https://doi.org/10.1007/s00251-006-0142-1
|
|
[3]
|
Herrmann, J.B., Muenstermann, M., Strobel, L., Schubert-Unkmeir, A., Woodruff, T.M., Gray-Owen, S.D., et al. (2018) Complement C5a Receptor 1 Exacerbates the Pathophysiology of N. meningitidis Sepsis and Is a Potential Target for Disease Treatment. mBio, 9, e01755-17.
https://doi.org/10.1128/mbio.01755-17
|
|
[4]
|
Cui, J., Shen, F., Zhang, C., Fu, C., Zhu, J. and Zhuang, T. (2026) The Multifaceted Roles of G Protein-Coupled Receptor C3aR1 in Disease: From Immunomodulation to Cancer Progression. Pathology—Research and Practice, 280, Article ID: 156386.
https://doi.org/10.1016/j.prp.2026.156386
|
|
[5]
|
de Freitas Oliveira-Tore, C., de Moraes, A.G., Plácido, H.M.B.S., Signorini, N.M.D.L., Fontana, P.D., da Piedade Batista Godoy, T., et al. (2025) Non-Canonical Extracellular Complement Pathways and the Complosome Paradigm in Cancer: A Scoping Review. Frontiers in Immunology, 16, Article 1519465.
https://doi.org/10.3389/fimmu.2025.1519465
|
|
[6]
|
Krieg, C. and Guglietta, S. (2025) The Complement System in Intestinal Inflammation and Cancer. Journal of Clinical Investigation, 135, e188348.
https://doi.org/10.1172/jci188348
|
|
[7]
|
Guttikonda, S.R., Sikkema, L., Tchieu, J., Saurat, N., Walsh, R.M., Harschnitz, O., et al. (2021) Fully Defined Human Pluripotent Stem Cell-Derived Microglia and Tri-Culture System Model C3 Production in Alzheimer’s Disease. Nature Neuroscience, 24, 343-354.
https://doi.org/10.1038/s41593-020-00796-z
|
|
[8]
|
Rodriguez, P., Pallais, J.P., He, R., Razzoli, M., McKee, J.L., Bock, H.A., et al. (2025) A Novel Class of Complement 3a Receptor Agonists and Antagonists Derived from the TLQP-21 Peptide. Journal of Medicinal Chemistry, 68, 19107-19121.
https://doi.org/10.1021/acs.jmedchem.5c01177
|
|
[9]
|
Li, L., Yin, Q., Tang, X., Bai, L., Zhang, J., Gou, S., et al. (2014) C3a Receptor Antagonist Ameliorates Inflammatory and Fibrotic Signals in Type 2 Diabetic Nephropathy by Suppressing the Activation of TGF-β/smad3 and IKBα Pathway. PLOS ONE, 9, e113639.
https://doi.org/10.1371/journal.pone.0113639
|
|
[10]
|
Matthews, K.W., Mueller-Ortiz, S.L. and Wetsel, R.A. (2004) Carboxypeptidase N: A Pleiotropic Regulator of Inflammation. Molecular Immunology, 40, 785-793.
https://doi.org/10.1016/j.molimm.2003.10.002
|
|
[11]
|
Bajic, G., Yatime, L., Klos, A. and Andersen, G.R. (2012) Human C3a and C3a DesArg Anaphylatoxins Have Conserved Structures, in Contrast to C5a and C5a DesArg. Protein Science, 22, 204-212.
https://doi.org/10.1002/pro.2200
|
|
[12]
|
Homan, E.A., Gilani, A., Rubio-Navarro, A., Johnson, M.A., Schaepkens, O.M., Cortada, E., et al. (2025) Complement 3a Receptor 1 on Macrophages and Kupffer Cells Is Not Required for the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease. eLife, 13, RP100708.
https://doi.org/10.7554/elife.100708
|
|
[13]
|
Pekna, M., Siqin, S., de Pablo, Y., Stokowska, A., Torinsson Naluai, Å. and Pekny, M. (2022) Astrocyte Responses to Complement Peptide C3a Are Highly Context-Dependent. Neurochemical Research, 48, 1233-1241.
https://doi.org/10.1007/s11064-022-03743-5
|
|
[14]
|
Li, Y., Sha, Y., Wang, H., He, L., Li, L., Wen, S., Sheng, L., Hu, W. and Zhou, H. (2021) Intracellular C3 Prevents Hepatic Steatosis by Promoting Autophagy and Very-Low-Density Lipoprotein Secretion. FASEB Journal, 35, e22037.
https://doi.org/10.1096/fj.202100856R
|
|
[15]
|
Muenstermann, M., Strobel, L., Klos, A., Wetsel, R.A., Woodruff, T.M., Köhl, J., et al. (2019) Distinct Roles of the Anaphylatoxin Receptors C3aR, C5aR1 and C5aR2 in Experimental Meningococcal Infections. Virulence, 10, 677-694.
https://doi.org/10.1080/21505594.2019.1640035
|
|
[16]
|
Nakazawa, D., Shida, H., Kusunoki, Y., Miyoshi, A., Nishio, S., Tomaru, U., et al. (2016) The Responses of Macrophages in Interaction with Neutrophils That Undergo NETosis. Journal of Autoimmunity, 67, 19-28.
https://doi.org/10.1016/j.jaut.2015.08.018
|
|
[17]
|
Li, Y., Zeng, H. and Zhong, X. (2025) Complement C3 in Panvascular Disease: A Central Integrator of Immune Signaling and Vascular Remodeling. Clinical Science, 139, 1373-1403.
https://doi.org/10.1042/cs20257865
|
|
[18]
|
Gragoll, C., Rawish, E., Schneider, M., et al. (2026) C3aR Blockade Attenuates Inflammation, Fibrosis, and Cardiac Dysfunction in Obesity-Associated HFpEF. Clinical Research in Cardiology.
|
|
[19]
|
Rodriguez, P., Laskowski, L.J., Pallais, J.P., Bock, H.A., Cavalco, N.G., Anderson, E.I., et al. (2024) Functional Profiling of the G Protein-Coupled Receptor C3ar1 Reveals Ligand-Mediated Biased Agonism. Journal of Biological Chemistry, 300, Article ID: 105549.
https://doi.org/10.1016/j.jbc.2023.105549
|
|
[20]
|
Yadav, M.K., Maharana, J., Yadav, R., Saha, S., Sarma, P., Soni, C., et al. (2023) Molecular Basis of Anaphylatoxin Binding, Activation, and Signaling Bias at Complement Receptors. Cell, 186, 4956-4973.e21.
https://doi.org/10.1016/j.cell.2023.09.020
|
|
[21]
|
Qin, J., Cai, C., Shan, M., Zhou, S., Shen, Q., Zhu, T., et al. (2026) Atypical Signaling, Ligand Recognition and Selective Agonist Discovery of Complement Receptor C5aR2. Cell Research, 36, 718-733.
https://doi.org/10.1038/s41422-026-01273-1
|
|
[22]
|
Shadid, A., Hok, K.D., Domozhirov, A.Y., Weng-Mills, T., Doursout, M., Banda, N.K., et al. (2025) Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease. Immune Network, 25, e32.
https://doi.org/10.4110/in.2025.25.e32
|
|
[23]
|
Litvinchuk, A., Wan, Y., Swartzlander, D.B., Chen, F., Cole, A., Propson, N.E., et al. (2018) Complement C3Ar Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer’s Disease. Neuron, 100, 1337-1353.e5.
https://doi.org/10.1016/j.neuron.2018.10.031
|
|
[24]
|
Wang, Y., Pandey, S., Weber, M., et al. (2025) Complement C3aR Deletion Does Not Attenuate Neurodegeneration in a Tauopathy Model or Alter Acute Inflammation-Induced Gene Expression Changes in the Brain. bioRxiv.
https://doi.org/10.1101/2025.06.16.660026
|
|
[25]
|
Ahmad, S., Pandya, C., Kindelin, A., Bhatia, K., Chaudhary, R., Dwivedi, A.K., et al. (2020) C3a Receptor Antagonist Therapy Is Protective with or without Thrombolysis in Murine Thromboembolic Stroke. British Journal of Pharmacology, 177, 2466-2477.
https://doi.org/10.1111/bph.14989
|
|
[26]
|
Pedersen, E.D., Løberg, E.M., Vege, E., Daha, M.R., Mæhlen, J. and Mollnes, T.E. (2009) In Situ Deposition of Complement in Human Acute Brain Ischaemia. Scandinavian Journal of Immunology, 69, 555-562.
https://doi.org/10.1111/j.1365-3083.2009.02253.x
|
|
[27]
|
Østergaard, J., Hansen, T.K., Thiel, S. and Flyvbjerg, A. (2005) Complement Activation and Diabetic Vascular Complications. Clinica Chimica Acta, 361, 10-19.
https://doi.org/10.1016/j.cccn.2005.04.028
|
|
[28]
|
Liu, J., Wang, D., Chen, Y., Sun, H., He, S., Wang, C., et al. (2013) 1H NMR-Based Metabonomic Analysis of Serum and Urine in a Nonhuman Primate Model of Diabetic Nephropathy. Molecular BioSystems, 9, 2645-2652.
https://doi.org/10.1039/c3mb70212j
|
|
[29]
|
Weng, M., Wu, X., Rao, S., Nie, K., You, D., Zheng, T., et al. (2025) C3a/C3aR Axis Is Involved in Diabetic Kidney Injury by Regulating Podocyte Mitophagy in Diabetic Nephropathy. International Journal of Molecular Medicine, 56, 1-15.
https://doi.org/10.3892/ijmm.2025.5664
|
|
[30]
|
Wang, Z., Xie, X., Li, J., Zhang, X., He, J., Wang, M., et al. (2021) Complement Activation Is Associated with Crescents in IgA Nephropathy. Frontiers in Immunology, 12, Article 676919.
https://doi.org/10.3389/fimmu.2021.676919
|
|
[31]
|
Buelli, S., Imberti, B. and Morigi, M. (2024) The Complement C3a and C5a Signaling in Renal Diseases: A Bridge between Acute and Chronic Inflammation. Nephron, 148, 712-723.
https://doi.org/10.1159/000538241
|
|
[32]
|
Mamane, Y., Chung Chan, C., Lavallee, G., Morin, N., Xu, L., Huang, J., et al. (2009) The C3a Anaphylatoxin Receptor Is a Key Mediator of Insulin Resistance and Functions by Modulating Adipose Tissue Macrophage Infiltration and Activation. Diabetes, 58, 2006-2017.
https://doi.org/10.2337/db09-0323
|
|
[33]
|
Paglialunga, S., Schrauwen, P., Roy, C., Moonen-Kornips, E., Lu, H., Hesselink, M.K.C., et al. (2007) Reduced Adipose Tissue Triglyceride Synthesis and Increased Muscle Fatty Acid Oxidation in C5L2 Knockout Mice. Journal of Endocrinology, 194, 293-304.
https://doi.org/10.1677/joe-07-0205
|
|
[34]
|
Xia, Z., Stanhope, K.L., Digitale, E., Simion, O., Chen, L., Havel, P., et al. (2004) Acylation-Stimulating Protein (ASP)/Complement C3adesArg Deficiency Results in Increased Energy Expenditure in Mice. Journal of Biological Chemistry, 279, 4051-4057.
https://doi.org/10.1074/jbc.m311319200
|
|
[35]
|
Savchenko, A.S., Borissoff, J.I., Martinod, K., De Meyer, S.F., Gallant, M., Erpenbeck, L., et al. (2014) VWF-Mediated Leukocyte Recruitment with Chromatin Decondensation by PAD4 Increases Myocardial Ischemia/Reperfusion Injury in Mice. Blood, 123, 141-148.
https://doi.org/10.1182/blood-2013-07-514992
|
|
[36]
|
Engström, G., Hedblad, B., Eriksson, K., Janzon, L. and Lindgärde, F. (2005) Complement c3 Is a Risk Factor for the Development of Diabetes: A Population-Based Cohort Study. Diabetes, 54, 570-575.
https://doi.org/10.2337/diabetes.54.2.570
|
|
[37]
|
Hertle, E., van Greevenbroek, M.M.J. and Stehouwer, C.D.A. (2012) Complement C3: An Emerging Risk Factor in Cardiometabolic Disease. Diabetologia, 55, 881-884.
https://doi.org/10.1007/s00125-012-2462-z
|
|
[38]
|
Jiang, K., Lu, S., Li, D., Liu, M., Jin, H., Lei, B., Wang, S., Long, K., He, S. and Zhong, F. (2023) Blockade of C5aR1 Alleviates Liver Inflammation and Fibrosis in a Mouse Model of NASH by Regulating TLR4 Signaling and Macrophage Polarization. Journal of Gastroenterology, 58, 894-907.
https://doi.org/10.1007/s00535-023-02002-w
|
|
[39]
|
Akhter, N., Lambay, A., Almotairi, R., Hamadi, A., Bhatia, K., Ahmad, S., et al. (2025) The Complex Role of the Complement C3a Receptor (C3aR) in Cerebral Injury and Recovery Following Ischemic Stroke. Cells, 14, Article 1440.
https://doi.org/10.3390/cells14181440
|
|
[40]
|
Engström, G., Hedblad, B., Janzon, L. and Lindgärde, F. (2007) Complement C3 and C4 in Plasma and Incidence of Myocardial Infarction and Stroke: A Population-Based Cohort Study. European Journal of Cardiovascular Prevention & Rehabilitation, 14, 392-397.
https://doi.org/10.1097/01.hjr.0000244582.30421.b2
|
|
[41]
|
Bhatia, K., Ahmad, S., Kindelin, A. and Ducruet, A.F. (2021) Complement C3a Receptor-Mediated Vascular Dysfunction: A Complex Interplay between Aging and Neurodegeneration. Journal of Clinical Investigation, 131, e144348.
https://doi.org/10.1172/jci144348
|
|
[42]
|
Sauter, R.J., Sauter, M., Reis, E.S., Emschermann, F.N., Nording, H., Ebenhöch, S., et al. (2018) Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point between Innate Immunity and Thrombosis. Circulation, 138, 1720-1735.
https://doi.org/10.1161/circulationaha.118.034600
|
|
[43]
|
Vazquez-Prada, K.X., Lam, J., Kamato, D., Xu, Z.P., Little, P.J. and Ta, H.T. (2021) Targeted Molecular Imaging of Cardiovascular Diseases by Iron Oxide Nanoparticles. Arteriosclerosis, Thrombosis, and Vascular Biology, 41, 601-613.
https://doi.org/10.1161/atvbaha.120.315404
|
|
[44]
|
Soehnlein, O. and Libby, P. (2021) Targeting Inflammation in Atherosclerosis—From Experimental Insights to the Clinic. Nature Reviews Drug Discovery, 20, 589-610.
https://doi.org/10.1038/s41573-021-00198-1
|
|
[45]
|
Ley, K. and Huo, Y. (2001) VCAM-1 Is Critical in Atherosclerosis. Journal of Clinical Investigation, 107, 1209-1210.
https://doi.org/10.1172/jci13005
|
|
[46]
|
Mueller-Ortiz, S.L., Calame, D.G., Shenoi, N., Li, Y. and Wetsel, R.A. (2017) The Complement Anaphylatoxins C5a and C3a Suppress IFN-β Production in Response to Listeria monocytogenes by Inhibition of the Cyclic Dinucleotide-Activated Cytosolic Surveillance Pathway. The Journal of Immunology, 198, 3237-3244.
https://doi.org/10.4049/jimmunol.1601420
|
|
[47]
|
Nordahl, E.A., Rydengård, V., Nyberg, P., Nitsche, D.P., Mörgelin, M., Malmsten, M., et al. (2004) Activation of the Complement System Generates Antibacterial Peptides. Proceedings of the National Academy of Sciences of the United States of America, 101, 16879-16884.
https://doi.org/10.1073/pnas.0406678101
|
|
[48]
|
Halstensen, T.S., Mollnes, T.E., Fausa, O. and Brandtzaeg, P. (1989) Deposits of Terminal Complement Complex (TCC) in Muscularis Mucosae and Submucosal Vessels in Ulcerative Colitis and Crohn’s Disease of the Colon. Gut, 30, 361-366.
https://doi.org/10.1136/gut.30.3.361
|
|
[49]
|
Krieg, C., Weber, L.M., Fosso, B., Marzano, M., Hardiman, G., Olcina, M.M., et al. (2022) Complement Downregulation Promotes an Inflammatory Signature That Renders Colorectal Cancer Susceptible to Immunotherapy. Journal for ImmunoTherapy of Cancer, 10, e004717.
https://doi.org/10.1136/jitc-2022-004717
|
|
[50]
|
Sodji, Q.H., Nambiar, D.K., Viswanathan, V., von Eyben, R., Colburg, D., Binkley, M.S., et al. (2022) The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer Cell Functions against Pancreatic Cancer. Cancer Research Communications, 2, 725-738.
https://doi.org/10.1158/2767-9764.crc-22-0069
|
|
[51]
|
Zhang, C., Hu, Y. and Shi, C. (2020) Targeting Natural Killer Cells for Tumor Immunotherapy. Frontiers in Immunology, 11, Article 60.
https://doi.org/10.3389/fimmu.2020.00060
|